ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Sharecare ( SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended June 30, 2023.
"Our integrated approach to delivering comprehensive care solutions has proven successful in enhancing user experiences, reducing costs, and measurably improving clinical outcomes across populations, whether people are managing high-risk and chronic conditions or simply require routine preventive care," said Jeff Arnold, chairman and CEO of Sharecare. "With our continued investments in generative AI, advocacy, and home care, we have the ability not only to generate personalized health insights derived from individual and aggregated data and deliver more tailored and engaging care solutions to people, but also to quickly identify health risks within diverse customer populations and close care gaps at scale, which is a win-win for our customers and their members."
Second Quarter 2023 Financial Results
All comparisons, unless otherwise noted, are to the three months ended June 30, 2022.
- Revenue of $110.4 million compared to $103.8 million, an increase of $6.6 million, or 6.3%.
- Net loss attributable to Sharecare of $35.1 million compared to $29.0 million, an increase to net loss attributable to Sharecare of $6.1 million. Net loss attributable to Sharecare in the second quarter of 2023 included $12.1 million in non-cash stock compensation; $1.4 million in non-operating, non-recurring costs; $8.2 million of reorganizational and severance costs; and $3.8 million of other non-cash or non-operational expense. Excluding these amounts, the adjusted net loss was $9.6 million in the current quarter.
- Adjusted EBITDA of $3.8 million compared to $2.1 million, an increase to adjusted EBITDA of $1.7 million.
- Net loss per share of $0.10 compared to $0.08, an increase to net loss per share of $0.02.
- Adjusted net loss per share, which excludes the impact of non-cash and non-operational amounts, was $0.03 compared to $0.02, an increase to adjusted net loss per share of $0.01.
Arnold added, “With the conclusion of our strategic review, which we announced in the quarter, the Board came to the unanimous decision that our three business channels – Enterprise, Provider, and Life Sciences – complement one another with a depth and breadth of capabilities that, together, create a unique platform-driven ecosystem built for scale. We are confident that the strategic alignment of these businesses allows us to seize new growth opportunities and serve our expanding customer base and their needs more effectively today and into the future, and we remain committed to maximizing shareholder value.”
“Sharecare’s financial health remains strong, and we are pleased with our performance in the second quarter, expanding adjusted EBITDA margins, substantially improved cash burn, and the robustness of our balance sheet – all of which will help us reach our goal of cash flow breakeven by year's end," said Justin Ferrero, president and chief financial officer of Sharecare.
Financial Outlook
Third Quarter 2023 Financial Guidance
For the three months ending September 30, 2023, the Company expects:
- Revenue in the range of $111 million to $113 million
- Adjusted EBITDA in the range of $8 million to $10 million
Fiscal 2023 Financial Guidance
For the twelve months ending December 31, 2023, the Company continues to expect:
- Revenue in the range of $452.5 million to $460 million
- Adjusted EBITDA in the range of $25 million to $30 million
Ferrero added, "While our business will continue to have some channel-level seasonality going forward, our expected adjusted EBITDA in the third quarter is indicative of the emerging underlying earnings power of Sharecare, driven in part by our $30 million annualized cost-savings initiative, which we also are on track to achieve by the end of 2023.”
Conference Call
The Company will host a conference call to review the second quarter results today, Wednesday, August 9, 2023, at 8:00 a.m. EDT. The call can be accessed by dialing (833) 636-1352 for U.S. participants or (412) 902-4148 for international participants, and referencing the Sharecare earnings call; or via live audio webcast, available online at https://investors.sharecare.com/. A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with U.S. GAAP, we believe the non-GAAP measures adjusted EBITDA, adjusted net loss, and adjusted loss per share are useful in evaluating our operating performance. We use adjusted EBITDA, adjusted net loss, and adjusted loss per share to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. In particular, we believe that the use of these non-GAAP measures is helpful to our investors as these metrics are used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures.
The calculations and reconciliations of historic adjusted EBITDA, adjusted net loss, and adjusted loss per share to net loss, the most directly comparable financial measure stated in accordance with GAAP, are provided below and in the accompanying financial tables. Investors are encouraged to review the reconciliations and not to rely on any single financial measure to evaluate our business.
We have not reconciled adjusted EBITDA guidance to net loss because we do not provide guidance for net loss or for items that we do not consider indicative of our ongoing performance, including, but not limited to, the impact of significant non-recurring items, as certain of these items are out of our control and/or cannot be reasonably predicted. Accordingly, reconciliations of adjusted EBITDA guidance to the corresponding U.S. GAAP measures are not available without unreasonable effort.
Adjusted EBITDA
We calculate adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization, (ii) interest income, (iii) interest expense, (iv) income tax expense, (v) other income (expense) (non-operating), (vi) share-based compensation, (vii) warrants issued with revenue contracts, (viii) amortization of non-cash payment for research and development, (ix) net costs associated with exiting a contract, (x) non-operating, non-recurring costs, (xi) reorganizational and severance costs, and (xii) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate the Company’s lines of business and services.
Adjusted Net Loss
We calculate adjusted net loss as net loss attributable to Sharecare, Inc. adjusted to exclude (i) amortization of acquired intangibles, (ii) amortization of deferred financing fees, (iii) change in fair value of warrant liability and contingent consideration, (iv) share-based compensation, (v) warrants issued with revenue contracts, (vi) amortization of non-cash payment for research and development, (vii) net costs associated with exiting a contract, (viii) non-operating, non-recurring costs, (ix) reorganizational and severance costs, and (x) acquisition related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate the Company’s lines of business and services.
Adjusted Loss Per Share
We calculate adjusted lost per share as adjusted net loss, as defined above, divided by the number of weighted average common shares outstanding - basic and diluted.
About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Important Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “outlook,” “target,” “reflect,” “on track,” “foresees,” “future,” “may,” “deliver,” “will,” “shall,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms, other comparable terminology (although not all forward-looking statements contain these words), or by discussions of strategy, plans, or intentions. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.
Forward-looking statements in this press release include, but are not limited to, statements regarding our long-term strategy and positioning, growth, globalization and other strategic cost optimization initiatives and the corresponding benefits, including long-term growth, margin improvement and cash flow improvements, and partnerships or other relationships with third parties or customers, in each case on our future growth objectives and statements regarding our future results and outlook, including those under the caption “Financial Outlook.”
We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results. For example, the Company’s Financial Outlook assumes business currently under contract and satisfaction by our customers of their contractual obligations under those agreements, which is not within the Company’s control. If a customer fails to satisfy its contractual obligations, actual revenue and Adjusted EBITDA could be negatively impacted. Descriptions of some of the other factors that could cause actual results to differ materially from these forward-looking statements are discussed in more detail in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including the Risk Factors section of the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2023. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Media Relations:
Jen Martin Hall
[email protected]
Investor Relations:
Bob East
[email protected]
SHARECARE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
June 30, Six Months Ended
June 30, 2023 2022 2023 2022 Revenue (inclusive of $18,045 and $8,051 of related party
revenue for the three months ended June 30, 2023 and
2022, respectively, and $36,793 and $15,619 of related
party revenue for the six months ended June 30, 2023 and
2022, respectively)$110,353 $103,823 $226,648 $204,533 Costs and operating expenses: Costs of revenue (exclusive of depreciation and
amortization; inclusive of $9,534 and $0 of related party
costs for three months ended June 30, 2023 and 2022,
respectively, and $20,396 and $0 of related party costs for
the six months ended June 30, 2023 and 2022, respectively) 62,948 53,238 130,840 104,730 Sales and marketing 14,959 14,155 30,309 28,666 Product and technology 17,035 17,680 37,843 37,101 General and administrative 35,371 43,491 69,490 99,489 Depreciation and amortization 14,184 10,901 28,965 20,778 Total costs and operating expenses 144,497 139,465 297,447 290,764 Loss from operations (34,144) (35,642) (70,799) (86,231)Other income (expense): Interest income 1,646 102 3,326 131 Interest expense (453) (539) (882) (1,031)Other (expense) income (2,631) 6,827 (2,201) 19,672 Total other (expense) income (1,438) 6,390 243 18,772 Loss before income tax expense (35,582) (29,252) (70,556) (67,459)Income tax expense (65) (269) (96) (361)Net loss (35,647) (29,521) (70,652) (67,820)Net loss attributable to noncontrolling interest in subsidiaries (504) (496) (850) (594)Net loss attributable to Sharecare, Inc.$(35,143) $(29,025) $(69,802) $(67,226) Net loss per share attributable to common stockholders, basic and diluted$(0.10) $(0.08) $(0.20) $(0.19)Weighted-average common shares outstanding, basic and diluted 354,049,808 347,334,401 353,490,234 346,122,333
SHARECARE, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)
2023 As of December 31,
2022Assets Current assets: Cash and cash equivalents$144,162 $182,508 Accounts receivable, net (net of allowance for doubtful accounts of $8,145 and $7,197, respectively) 123,856 116,877 Other receivables 2,329 4,114 Prepaid expenses 10,420 12,612 Other current assets 4,890 4,515 Total current assets 285,657 320,626 Property and equipment, net 4,595 5,082 Other long-term assets 20,426 20,362 Intangible assets, net 152,763 163,114 Goodwill 191,946 191,817 Total assets$655,387 $701,001 Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity Current liabilities: Accounts payable$25,719 $8,838 Accrued expenses and other current liabilities 79,569 81,627 Deferred revenue 6,931 9,032 Contract liabilities, current 768 1,535 Total current liabilities 112,987 101,032 Warrant liabilities 3,307 2,441 Long-term debt 364 — Other long-term liabilities 9,565 16,723 Total liabilities 126,223 120,196 Commitments and contingencies Series A convertible redeemable preferred shares, $0.0001 par value; 5,000,000
shares authorized; 5,000,000 shares issued and outstanding, aggregate
liquidation preference of $50,000 as of June 30, 2023 and December 31, 2022 58,205 58,205 Stockholders’ equity: Common stock, $0.0001 par value; 600,000,000 and 600,000,000 shares
authorized; 356,593,964 and 354,463,620 shares issued and outstanding as of
June 30, 2023 and December 31, 2022, respectively 35 35 Additional paid-in capital 1,139,594 1,120,024 Accumulated other comprehensive loss (2,370) (2,794)Accumulated deficit (666,677) (595,820)Total Sharecare stockholders’ equity 470,582 521,445 Noncontrolling interest in subsidiaries 377 1,155 Total stockholders’ equity 470,959 522,600 Total liabilities, redeemable convertible preferred stock and stockholders’ equity$655,387 $701,001
SHARECARE, INC.
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(Unaudited)
(In thousands)
June 30, Six Months Ended
June 30, 2023 2022 2023 2022 Net loss$(35,647) $(29,521) $(70,652) $(67,820)Add: Depreciation and amortization 14,184 10,901 28,965 20,778 Interest income (1,646) (102) (3,326) (131)Interest expense 453 539 882 1,031 Income tax expense 65 269 96 361 Other expense (income) 2,631 (6,827) 2,201 (19,672)Share-based compensation 12,149 18,177 22,116 51,287 Warrants issued with revenue contracts 14 14 28 34 Amortization of non-cash payment for research and development 1,190 424 2,380 847 Net costs associated with exiting a contract(a) 505 1,249 1,222 2,923 Non-operating, non-recurring costs(b) 1,427 2,281 3,142 5,037 Reorganizational and severance costs(c) 8,224 3,482 18,036 6,059 Acquisition-related costs 267 1,249 825 3,224 Adjusted EBITDA(d)$3,816 $2,135 $5,915 $3,958
SHARECARE, INC.
RECONCILIATION OF GAAP NET LOSS ATTRIBUTABLE TO SHARECARE TO ADJUSTED NET LOSS AND ADJUSTED LOSS PER SHARE
(Unaudited)
(In thousands, except share and per share data)
June 30, Six Months Ended
June 30, 2023 2022 2023 2022 Net loss attributable to Sharecare, Inc.$(35,143) $(29,025) $(69,802) $(67,226)Add: Amortization of acquired intangibles(a) 1,633 1,631 3,265 3,263 Amortization of deferred financing fees — 70 31 138 Change in fair value of warrant liability and contingent consideration 96 (6,374) (42) (18,742)Share-based compensation 12,149 18,177 22,116 51,287 Warrants issued with revenue contracts 14 14 28 34 Amortization of non-cash payment for research and development 1,190 424 2,380 847 Net costs associated with exiting a contract(b) 505 1,249 1,222 2,923 Non-operating, non-recurring costs(c) 1,427 2,281 3,142 5,037 Reorganizational and severance costs(d) 8,224 3,482 18,036 6,059 Acquisition-related costs 267 1,249 825 3,224 Adjusted net loss(e)$(9,638) $(6,822) $(18,799) $(13,156) Weighted-average common shares outstanding, basic and diluted 354,049,808 347,334,401 353,490,234 346,122,333 Loss per share$(0.10) $(0.08) $(0.20) $(0.19)Adjusted loss per share$(0.03) $(0.02) $(0.05) $(0.04)
